The rate of onset of action of d-tubocurarine (64 patients) or alcuronium (36 patients) was studied electromyographically in 100 children who had abdominal, bone or cerebral tumours. It was found that there was a significantly delayed onset (over three times longer than controls) or additional doses were required in patients with malignant liver, renal and bone tumours who received dotubocurarine. The onset of alcuronium blockade was also prolonged but to a lesser extent. When tumours with an abnormal prolongation of onset of relaxation were successfully treated by chemotherapy and/or surgery, the response reverted to normal. Children with benign tumours or masses had normal responses. In contrast, neuroblastomas were associated with little prolongation of onset. Cerebral tumours showed a variable response, with the observed changes being unreliable indicators of degree of malignancy.
intraoperative intravenous opioid. When a stable EMG trace was obtained, either 0.66 mg/kg d-tubocurarine or 0.3 mglkg alcuronium was given. From the recordings taken, three measurements were made: 1. Time from injection until 25% neuromuscular block; 2. Time from onset of paralysis to 25% neuromuscular block; and 3. Time from 25 to 75% neuromuscular block.
One hundred normal children were used as controls -66 received alcuronium and 34 d-tubocurarine. The above three measurements, as well as time to maximum block, were made to determine control values (Table 1) .
The pathology specimens were examined for size and the nature and degree of malignancy, including the presence of necrosis. Size was graded as: 1. small, less than 10 cm in diameter; 2. large, over 10 cm; or, 3. widespread.
Malignancy was scored: 1. benign or low grade; 2. malignant; or, 3 . malignant and necrotic.
The combined total for size and degree of malignancy is the pathological score for each patient. The prolongation of the onset of action was scored for each of the time measurements made: O. 0-20% longer than controls; 1. 20-100% longer than controls; 2. 100-300% longer than controls; 3. 300-600% longer than controls; 4. Over 600%; 5. Level of paralysis did not reach 75% with the standard doses indicating a significant increase in dose requirement. Although a score of 2 indicates a definitely prolonged response, scores of 3, 4, and 5 are clinically significantly abnormal.
RESULTS
One hundred IEMG responses in children with tumours who received d-tubocurarine or alcuronium are presented. 1. ABDOMINAL TUMOURS (a) Wilms' Tumour. Twenty-four studies were conducted on 21 patients, 9 with alcuronium and 15 with d-tubocurarine. Most patients who had not been treated with chemotherapy had pathological scores of 5 or 6, while those who had been treated ranged from 2 to 5. The prolongation of onset was usually greater with d-tubocurarine than alcuronium but, after chemotherapy, the responses 2S % N.M.BLOCK 7S 100 i
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'-----.,,''''0"'''",7, ______ '00% FIGURE 2.--Prolonged onset of neuromuscular block. The numbers refer to the 'prolongation scores'. The shaded area includes the range of responses for a score of 3. Other scores refer to the area between the times in which the number lies. It can be seen that score 5 implies a very slow onset and inadequate dose.
in both groups returned to nearly normal ( Table 2 ). Figure 3 shows a very slow response, with two additional doses of d-tubocurarine being required to produce adequate paralysis in a child with Wilms' tumour. These incremental doses were used to calculate the ED9/ which was 1588 Jlglkg -over three times normal. Following chemotherapy, the response of this child to alcuronium was normal, indicating successful treatment of the tumour. One infant who was suspected of having a Wilms' tumour had a normal EMG response. A nodular kidney, the result of pyelonephritis, was found at surgery.
(b) Liver tumours. Five patients were studied on eight occasions. They had hepatoblastoma (2), embryonal hepatic sarcoma (2) and benign nodular hyperplasia (1).
One patient showed marked resistance to both d-tubocurarine and alcuronium prior to chemotherapy, with recovery to a nearly normal response after a course of chemotherapy given prior to removal of the remaining tumour. Two other patients were resistant to d-tubocurarine and one to alcuronium (on two occasions a few days apart). The prediction that a mass in the liver of one child with a normal EMG response was benign, proved correct when the pathology showed benign nodular hyperplasia. 3 (c) Neuroblastoma. This is one of the most common and most malignant tumours in childhood. It arises in cells in the sympathetic nervous system derived from the embryonic neural crest. 4 Such tumours can develop in a variety of sites, but are most commonly associated with the adrenal gland or sympathetic chain. Although they can be very malignant, spontaneous remission can occur, possibly through activation of the host's immune mechanisms. In the seven patients studied, three who had been treated with chemotherapy had a normal response. One who had widespread disease had a normal response to a1curonium, while one not treated with chemotherapy did not reach 75% paralysis with d-tubocurarine 0.66 mglkg. These results do not show the consistency found with liver and kidney tumours. This inconsistency may be related to the varying natural history of these tumours. 
BONE TUMOURS
The most common malignant bone tumours in children are Ewing's Tumour and osteosarcoma. 5 The pathology scores in the patients with these tumours ranged from 4-6, the majority being 5.
Ewing's Tumour patients had a greater prolongation of onset of neuromuscular block after d-tubocurarine than after a1curonium. Table 3 shows that regression towards a normal EMG response following chemotherapy was greater in patients with Ewing's Tumour than in those with osteosarcoma. This finding accords with general clinical experience that the former are more responsive to chemotherapy.
Three cases illustrate the relation between chemotherapy, the effect oftreatment and the rate of onset of neuromuscular block. Figure 4 shows the slow onset of blockade with d-tubocurarine in a 14-year-old girl with osteosarcoma when the tumour was biopsied and then when it was resected following chemotherapy two months later. The second response was also slow and the tumour was found to be more than 50% viable when examined pathologically. A I5-year-old girl with a previously diagnosed Ewing's Tumour which had been treated with chemotherapy, presented again for resection following a suspicious scan. The EMG showed that the rate of onset of neuromuscular block was normal and no active tumour, only fibrosis, was found.
A IO-year-old girl who had been treated with chemotherapy was studied when she had her leg amputated. The onset of paralysis was slightly slower than normal ( Figure 5 ). The pathology sections showed that there was less than 10% viable tumour in the specimen. Three months later, she presented for a dental anaesthestic and had a normal response to alcuronium. Two patients who had benign tumours had normal onset times, one following d-tubocurarine and the other following alcuronium.
Although prolongation of onset of neuromuscular block suggests the lesion may be a malignant tumour, we had a patient with more than 10% viable osteosarcoma who had a normal onset.
In conclusion, we found most patients with malignant bone tumours had a slow onset of neuromuscular block and that regression towards normal after chemotherapy or amputation suggested that the treatment had been of some benefit. However, there are occasional exceptions.
INTRACRANIAL TUMOURS
There were 35 children with intracranial tumours or masses in this study (Table 4 ). Thirteen had astrocytomas and 11 of these received d-tubocurarine. The EMG responses in these patients varied from no delay in onset of neuromuscular block in 5 patients (scores of 0-1) to significant prolongation in three (scores of 4 or 5). Astrocytomas are often low grade tumours and relatively few are very malignant. 6 Two of the three with onset time scores of 4 and 5 were medium grade and one (Score 4) was malignant, so that despite the very wide range of response the most prolonged responses were in the patients with the least benign tumours receiving d-tubocurarine. Only two received alcuronium and one of these, with a medium grade tumour, had an onset time score of 2.
Craniopharyngiomas generally are locally invasive rather than malignant tumours 7 but three out of five (2 d-tubocurarine, 1 alcuronium) showed prolongation of onset of neuromuscular block (onset time scores 2,5, 3). This tumour may be associated with a variety of endocrine dysfunctions, which may have resulted in this effect. Ependymomas tend to run a malignant course. 8 All our eight patients had pathological scores supporting this, yet only three who received alcuronium had prolonged onset (3, 2, 2) while those receiving d-tubocurarine had a normal onset time. Three children with medulloblastomas, usually a malignant tumour, had normal responses.
The other notable cases included a child with a germinoma who did not reach 75% neuromuscular block with alcuronium 0.3 mg/kg. A prolonged onset (score 4) was seen in a patient with a meningeal sarcoma. A child who had an intracranial arterio-venous malformation, as might be expected, had a normal response to d-tubocurarine. In summary, the prolongation of onset (25-75% scores) of d-tubocurarine and alcuronium was a much less reliable indicator of the degree of malignancy of intracranial tumours than abdominal and bone tumours. However, with some, the degree of prolongation did relate. to malignancy.
It is possible that the variable response to nondepolarizing muscle relaxants in cerebral tumours is dependant on permeability of the 'blood brain barrier'. Normally, ionised drugs do not cross the blood brain barrier easily. Possibly with very malignant tumours, it is disrupted, making access easier for these drugs. If the tumour contains potential binding sites, increased access to the tumour would account for the greater doses needed in some patients.
DISCUSSION
This study has demonstrated that, with certain types of tumour, in particular those ofliver, kidney and bones, malignancy is associated with a slow onset of paralysis following d-tubocurarine and, to a lesser extent, alcuronium. It also showed that the abnormality reverted to a normal response when the tumour was removed completely or was successfully treated with chemotherapy. In patients suspected of having tumours ofthe above organs, a normal response indicated that the tumour or mass was benign. The predictive value of onset times for neuromuscular block was much less reliable with intracranial tumours.
This study was conducted with standard doses of d-tubocurarine and alcuronium. Resistance to the drugs showed up as a slow onset, or the need for additional doses when the initial response was inadequate. The patient shown in Figure 3 , required two aditional doses. When the ED95 was calculated on a log pro bit graph, the required dose was over three times normal -1590 ~g/kg compared to 450 ~g/kg.2 It has been demonstrated that alcuronium 0.2 mg/kg only produced 87% neuromuscular block. The time to reach the maximum block was longer than if 0.3 mglkg was given, when 95% block was achieved. lo Thus, prolonged onset time may be regarded as an indication of a greater dose requirement. The use of incremental dose responses to calculate ED 95 , would be an alternative way to demonstrate resistance.
The reason for the slow onset of paralysis and the need, sometimes, for a larger dose is not known. It is possible that the tumours contain some substance that binds the relaxant so that less reaches the receptor. The tumours where the changes occur most consistently are in the high blood flow organs, liver and kidney. If this theory is correct, any chemotherapeutic agent which could be attached to d-tubocurarine could be delivered in higher concentration to the susceptible tumour.
Anaesthesia and Intensive Care, Vo!. 18, No. 4, November, 1990 Plasma protein electrophoresis was carried out on the plasma of 15 patients to determine whether tumours caused a significant increase in anyone fraction that might provide an increased binding site for the relaxant. No consistent abnormal peak was found.
Another possibility is that some tumours produce antibodies or some substance that affects the receptor sites of muscle or their responsiveness to the blocking action of muscle relaxants.
The practical conclusion from this study is that patients with certain tumours may require larger doses of relaxant and that the onset of paralysis may be slow. In some types of tumours, the electromyographic response to d-tubocurarine and, to a lesser extent, alcuronium may differentiate malignant from nonmalignant tumours and successful from unsuccessful treatment with chemotherapy.
